264 related articles for article (PubMed ID: 9053492)
1. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
Giralt S; Weber D; Colome M; Dimopoulos M; Mehra R; Van Besien K; Gajewski J; Andersson B; Khouri I; Przepiorka D; von Wolff B; Delasalle K; Korbling M; Seong D; Alexanian R; Champlin R
J Clin Oncol; 1997 Feb; 15(2):667-73. PubMed ID: 9053492
[TBL] [Abstract][Full Text] [Related]
2. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
[TBL] [Abstract][Full Text] [Related]
3. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
[TBL] [Abstract][Full Text] [Related]
6. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
7. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
8. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.
van der Wall E; Horn T; Bright E; Passos-Coehlo JL; Bond S; Clarke B; Altomonte V; McIntyre K; Vogelsang G; Noga SJ; Davis JM; Thomassen J; Ohly KV; Lee SM; Fetting J; Armstrong DK; Davidson NE; Hess AD; Kennedy MJ
Br J Cancer; 2000 Dec; 83(11):1405-11. PubMed ID: 11076645
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
10. Graft versus host disease in autologous stem cell transplantation.
Marin GH; Porto A; Prates V; Napal J; Etchegogen O; Rubens L; Bordone J; Castelletto R; Buschiazzo H; Morales V; Milone J
J Exp Clin Cancer Res; 1999 Jun; 18(2):201-8. PubMed ID: 10464707
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
Vogelsang G; Bitton R; Piantadosi S; Altomonte V; Horn T; Jones R; Miller C; Marcellus D; Abrams R; Hess A
Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
[TBL] [Abstract][Full Text] [Related]
14. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.
Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A
Bone Marrow Transplant; 1998 Sep; 22(5):449-55. PubMed ID: 9733268
[TBL] [Abstract][Full Text] [Related]
17. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells.
Miura Y; Ueda M; Takami A; Shiobara S; Nakao S; Hess AD
Bone Marrow Transplant; 2003 Oct; 32(8):785-90. PubMed ID: 14520422
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
